A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer

PURPOSE: Mesenchymal–epithelial transition factor (MET) is expressed in gastric cancer and associated with poor clinical outcomes. We assessed activity, safety, and pharmacokinetics of emibetuzumab, a bivalent monoclonal anti-MET antibody that blocks ligand-dependent and ligand-independent MET signa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Daisuke, Chung, Hyun Cheol, Oh, Do-Youn, Park, Se Hoon, Kadowaki, Shigenori, Kim, Yeul Hong, Tsuji, Akihito, Komatsu, Yoshito, Kang, Yoon-Koo, Uenaka, Kazunori, Wijayawardana, Sameera R., Wacheck, Volker, Wang, Xuejing, Yamamura, Ayuko, Doi, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686250/
https://www.ncbi.nlm.nih.gov/pubmed/29071414
http://dx.doi.org/10.1007/s00280-017-3445-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686250/
https://www.ncbi.nlm.nih.gov/pubmed/29071414
http://dx.doi.org/10.1007/s00280-017-3445-z

Ejemplares similares